ACM
UTHR icon

Atika Capital Management’s United Therapeutics UTHR Stock Holding History

Atika Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$6.69M – 114
2021
Q1 		$6.69M Buy
+400
New +$66.7K 0.58% 67
2016
Q3 		– Sell
-29,500
Closed -$3.13M – 77
2016
Q2 		$3.13M Buy
29,500
+7,000
+31% +$781K 1.34% 25
2016
Q1 		$2.51M Buy
+22,500
New +$2.85M 1.52% 26

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Atika Capital Management's UTHR Position: Q1 2026 in Review

Atika Capital Management opened a new position in United Therapeutics (UTHR) in Q1 2026: 12,350 shares worth $7.32M. The stake represents 0.92% of the portfolio and ranks #32 among its holdings. This is a return to the name: Atika Capital Management previously reported a position in UTHR as recently as Q4 2024.

Atika Capital Management first reported a position in UTHR in Q1 2015 and has held it in 9 quarters since. The position peaked at $15.1M in Q4 2022. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Atika Capital Management held 12,350 shares of United Therapeutics worth $7.32M as of Q1 2026.
  • United Therapeutics was a new Atika Capital Management position in Q1 2026.
  • United Therapeutics made up 0.92% of Atika Capital Management's portfolio in Q1 2026, its #32 holding.
  • Atika Capital Management first reported a position in United Therapeutics in Q1 2015 and has held it in 9 quarters since.
  • Atika Capital Management's United Therapeutics position peaked at $15.1M in Q4 2022.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.